


Brønsted Acid-assisted Intramolecular Aminohydroxylation of *N*-Alkenylsulfonamides under Heavy Metal-free Conditions

Katsuhiko Moriyama,* Yuta Izumisawa, and Hideo Togo*

Department of Chemistry, Graduate School of Science, Chiba University, Yayoi-cho 1-33, Inage-ku, Chiba 263-8522, Japan

S Supporting Information


ABSTRACT: The intramolecular aminohydroxylation of *N*-alkenylsulfonamides proceeded under heavy metal-free conditions to give substituted prolinol derivatives in high yields. Oxone activated by catalytic Brønsted acid worked well as an electrophilic oxidant for this reaction.




The aminooxygenation of olefins is a very important strategy to directly provide 1,2-aminoalcohol derivatives that serve as useful building blocks in the synthesis of drugs and natural products.^{1,2} In particular, the intramolecular aminooxygenation of *N*-protected alkenes furnishes nitrogen-containing heterocycles that possess a variety of biological activities.³ Previously, reported methods required the use of heavy metals, such as Os,⁴ Pd,⁵ Cu,⁶ and Au,⁷ for the intramolecular aminooxygenation of *N*-protected alkenes (Scheme 1, eq 1). Heavy metal-free

Scheme 1. Intramolecular Aminohydroxylation of *N*-Protected Alkenes

Previous work



This work



reactions of *N*-protected amines with iodine reagents (phenyliodine(III) bis(trifluoroacetate) (PIFA),⁸ NIS,⁹ iodosylbenzene,¹⁰ and chiral arylidene(III) diacetate¹¹) were developed as sustainable strategies. However, the reactions with *N*-alkenylsulfonamides produced a stoichiometric amount of organic waste derived from the organic oxidant. We report here a heavy metal-free intramolecular aminohydroxylation of *N*-alkenylsulfonamides using a Brønsted acid-assisted inorganic oxidant, which is the simplest aminooxygenation method and produces no stoichiometric amount of organic waste (Scheme 1, eq 2).


Initially, we optimized the reaction conditions for the intramolecular aminohydroxylation of *N*-alkenylsulfonamides (Table 1). When **1a** was treated with Oxone (2KHSO₅·KHSO₄·K₂SO₄) in a mixture of MeCN and H₂O (1:1) at room temperature, **2a** was obtained in 74% yield (entry

1). The addition of TsOH·H₂O as Brønsted acid to activate the cyclization increased the yield of **2a** (entry 2). The use of other Brønsted acids, such as PhCO₂H, (PhO)₂P(O)OH, and (CF₃SO₂)₂NH, decreased the yield of **2a** (entries 3–5). The use of MeNO₂, AcOEt, and CH₂Cl₂ instead of MeCN as organic solvent was not effective as a organic solvent for the intramolecular aminohydroxylation (entries 6–8). Under basic conditions, the reaction with K₂CO₃ (1.5 equiv) became less effective, and increasing the amount of K₂CO₃ to 3.0 equiv had no effect whatsoever on the transformation of **1a** into **2a** (entry 9). Raising the temperature of the reaction to 50 °C furnished **2a** in a quantitative yield (entry 10). The use of other oxidants and changing the ratio of MeCN to H₂O as solvent at 50 °C had negligible effects compared to the use of Oxone in a 1:1 mixture of MeCN and H₂O (entries 11–16). Interestingly, the reaction in H₂O produced a cyclization product in 81% yield (entry 13).

Then, we investigated the scope of the heavy metal-free intramolecular aminohydroxylation of *N*-alkenylsulfonamides **1** under the optimized reaction conditions (Table 2). The reaction of *N*-alkenylsulfonamides bearing other sulfonyl groups, such as 4-fluorobenzenesulfonyl (**1b**), 4-nitrobenzenesulfonyl (**1c**), *n*-butanesulfonyl (**1d**), and (*S*)-camphorsulfonyl (**1e**), gave corresponding products (**2b–2e**) in high yields (78–97%) (entries 1–4). When monoalkyl- and dialkyl-substituted alkenylsulfonamides (**1f–1j**) were treated with Oxone (1.5 or 2.0 equiv), cyclization products (**2f–2j**) were obtained in excellent yields (91–98%) (entries 5–9). The reaction of *N*-sulfonyl-2-allylcyclohexylamines (**1k** and **1l**) and *N*-sulfonyl-2-allylaniline (**1m**) with Oxone (2.0 equiv) in a 2:1 mixture of MeCN and H₂O also provided hexahydroindoline derivatives (**2k** and **2l**) and the indoline derivatives (**2m**) in high yields (78–90%), respectively (entries 10–12). π -Electron-rich disubstituted internal alkenes (**1n** and **1o**) and disubstituted terminal alkene (**1p**) were efficiently converted into prolinol derivatives bearing a secondary alcohol group (**2n** and **2o**) and a quaternary carbon center (**2p**), respectively, in high yields (78–91%) (entries 13–15). Moreover, *N*-alkenylsulfonamide bearing a

Received: July 19, 2012

Published: October 10, 2012

Table 1. Screening of Optimal Conditions for Intramolecular Aminohydroxylation of **1a**


entry	oxidant	additive	conditions	time (h)	yield of 2a (%)
1	Oxone		MeCN:H ₂ O (1:1), rt	24	74
2	Oxone	TsOH·H ₂ O	MeCN:H ₂ O (1:1), rt	24	84
3	Oxone	PhCO ₂ H	MeCN:H ₂ O (1:1), rt	24	59
4	Oxone	(PhO) ₂ P(O)OH	MeCN:H ₂ O (1:1), rt	24	68
5	Oxone	(CF ₃ SO ₂) ₂ NH	MeCN:H ₂ O (1:1), rt	24	66
6	Oxone	TsOH·H ₂ O	MeNO ₂ :H ₂ O (1:1), rt	24	6
7	Oxone	TsOH·H ₂ O	AcOEt:H ₂ O (1:1), rt	24	14
8	Oxone	TsOH·H ₂ O	CH ₂ Cl ₂ :H ₂ O (1:1), rt	24	5
9	Oxone	K ₂ CO ₃	MeCN:H ₂ O (1:1), rt	24	44 ^a (0) ^b
10	Oxone	TsOH·H ₂ O	MeCN:H ₂ O (1:1), 50 °C	10	>99
11	Oxone	TsOH·H ₂ O	MeCN:H ₂ O (2:1), 50 °C	10	92
12	Oxone	TsOH·H ₂ O	MeCN:H ₂ O (1:2), 50 °C	10	91
13	Oxone	TsOH·H ₂ O	H ₂ O, 50 °C	20	81
14	H ₂ O ₂	TsOH·H ₂ O	MeCN:H ₂ O (1:1), 50 °C	20	0
15	TBHP	TsOH·H ₂ O	MeCN:H ₂ O (1:1), 50 °C	20	0
16	<i>t</i> -BuOCl	TsOH·H ₂ O	MeCN:H ₂ O (1:1), 50 °C	10	84

^aNumber indicates the yield when the reaction was carried out with K₂CO₃ (1.5 equiv) and obtained 56% recovery of **1a**. ^bNumber in parentheses indicates the yield when the reaction was carried out with K₂CO₃ (3.0 equiv) and obtained >99% recovery of **1a**.

hydroxy group (**1q**) also provided 4-hydroxyprolinol derivative (**2q**) in 91% yield (entry 16). Unfortunately, the reaction of diastereotopic *N*-alkenyl sulfonamides gave moderate to low diastereoselectivities (*dr* = 77:23–54:46).

The proposed reaction mechanism for the Brønsted acid catalyzed intramolecular aminohydroxylation of *N*-alkenylsulfonamides is depicted in Scheme 2.

The catalytic Brønsted acid (TsOH or KSO₄H) activates Oxone as an electrophilic oxidant to form activated peroxymonosulfate intermediate (**A**)¹² in situ. Intermediate (**A**) promotes the intramolecular aminohydroxylation of *N*-alkenylsulfonamides, particularly electron-poor monosubstituted olefins. This reaction proceeds through a tandem reaction via the epoxidation of olefins, followed by the *exo*-selective intramolecular amination of epoxides.^{12,13}

Once prolinol derivatives **2** are formed, they are readily transformed into *N*-sulfonyl proline derivatives **3** by the treatment with (diacetoxyiodo)benzene (DIB) (2.2 equiv) and 2,2,6,6-tetramethylpiperidine 1-oxyl (TEMPO) (10 mol %) in a 1:1 mixture of MeCN and H₂O at room temperature (Scheme 3).¹⁴ The reactions of **2a**, **2g**, **2i**, **2j**, and **2k** gave corresponding

products **3a**, **3g**, **3i**, **3j**, and **3k** in high yields (80–>99%), respectively.

Finally, we investigated the possibility of synthesizing of proline ethyl ester **5a** through the cleavage of the sulfonyl groups of *N*-sulfonylproline **3a** under mild conditions (Scheme 4). **3a** was treated with EtI and K₂CO₃ to obtain *N*-tosyl-protected proline ethyl ester **4a** in a quantitative yield. Removal of the tosyl group in **4a** with phenol in aqueous HBr solution and AcOH¹⁵ provided desired proline ethyl ester **5a** as a hydrobromide salt in 94% yield.

In conclusion, we have developed an intramolecular aminohydroxylation of *N*-alkenylsulfonamides (**1**) that proceeds under heavy metal-free conditions. This reaction, which was promoted by a Brønsted acid catalyst, activated a peroxymonosulfate complex to obtain *N*-sulfonyl prolinol derivatives (**2**). Moreover, **2** were transformed into *N*-sulfonyl proline derivatives (**3**) by oxidation using a DIB/TEMPO system and **3** was, in turn, converted into proline ethyl ester (**5a**) by desulfonylation under mild conditions.

EXPERIMENTAL SECTION

General Procedure. ¹H NMR spectra were measured on a 400 MHz spectrometer. Chemical shifts were recorded as follows: chemical shift in ppm from internal tetramethylsilane on the δ scale, multiplicity (s = singlet; d = doublet; t = triplet; q = quartet; m = multiplet; br = broad), coupling constant (Hz), integration, and assignment. ¹³C NMR spectra were measured on a 100 MHz spectrometer. Chemical shifts were recorded in ppm from the solvent resonance employed as the internal standard (deuteriochloroform at 77.0 ppm). High-resolution mass spectra (HRMS) were performed by orbitrap mass spectrometers. Characteristic peaks in the Infrared (IR) spectra are recorded in wave numbers, cm⁻¹. Melting points are reported as uncorrected. Thin-layer chromatography (TLC) was performed using 0.25 mm silica gel plate (60F-254). The products were purified by column chromatography on silica gel 60 (63–200 mesh). Visualization was accomplished by UV light (254 nm), anisaldehyde, KMnO₄, and phosphomolybdic acid. *N*-Alkenyl sulfonamides **1a–1e**, **1h–1j**, and **1n–1p**,^{16a} **1f** and **1g**,^{16b} **1k** and **1l**,^{16c,d} **1m**,^{16e} and **1q**^{4g} were prepared according to the literature procedure. Spectroscopic data of **2a**,^{6b} **2h**,^{17a} **2i**,^{6b} **2m**,^{6b} **2q**,^{4g} **3a**,^{17b} and **4a**^{17c} were in accord with those reported in the literature.

4-Fluoro-*N*-(pent-4-en-1-yl)benzenesulfonamide (1b). Colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 1.57 (quin, *J* = 7.1 Hz, 2H), 2.05 (q, *J* = 6.8 Hz, 2H), 2.96 (q, *J* = 7.1 Hz, 2H), 4.91 (brs, 1H), 4.92–5.00 (m, 2H), 5.70 (ddt, *J* = 17.2, 10.5, 6.8 Hz, 1H), 7.19 (d, *J* = 8.8 Hz, 2H), 7.90 (dd, *J* = 8.8, 5.0 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 28.6, 30.5, 42.6, 115.6, 116.3 (d, *J*_{C–F} = 23.0 Hz) (2C), 129.7 (d, *J*_{C–F} = 8.6 Hz) (2C), 136.0 (d, *J*_{C–F} = 3.8 Hz), 137.0, 165.0 (d, *J*_{C–F} = 254.8 Hz). IR (neat) 3286, 2938, 1422, 1328, 1237, 1155 cm⁻¹. MS (ESI) calcd for C₁₁H₁₅FNO₂S [M + H]⁺ 244.0802, found 244.0801.

***N*-(Pent-4-en-1-yl)butane-1-sulfonamide (1d).** Colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 0.96 (t, *J* = 7.4 Hz, 3H), 1.46 (sext, *J* = 7.4 Hz, 2H), 1.67 (quin, *J* = 7.2 Hz, 2H), 1.73–1.82 (m, 2H), 2.13 (q, *J* = 7.1 Hz, 2H), 2.97–3.04 (m, 2H), 3.12 (q, *J* = 7.2 Hz, 2H), 4.39–4.49 (brm, 1H), 4.99–5.09 (m, 2H), 5.79 (ddt, *J* = 17.2, 10.3, 7.1 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 13.6, 21.5, 25.6, 29.4, 30.7, 42.6, 52.3, 115.6, 137.2. IR (neat) 3289, 2962, 1432, 1322, 1144, 1082 cm⁻¹. MS (ESI) calcd for C₉H₂₀NO₂S [M + H]⁺ 206.1209, found 206.1212.


(1*S*)-10-Camphor-*N*-(pent-4-en-1-yl)sulfonamide (1e). Colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 0.92 (s, 3H), 1.03 (s, 3H), 1.42–1.50 (m, 1H), 1.71 (quin, *J* = 7.3 Hz, 2H), 1.91–2.09 (m, 3H), 2.10–2.27 (m, 4H), 2.36–2.43 (m, 1H), 2.91 (d, *J* = 15.2 Hz, 1H), 3.10–3.24 (m, 2H), 3.39 (d, *J* = 15.2 Hz, 1H), 4.97–5.10 (m, 2H), 5.13–5.20 (brm, 1H), 5.80 (ddt, *J* = 17.2, 10.5, 6.9 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 19.5, 19.9, 26.6, 27.0, 29.2, 30.7, 42.8, 42.9, 43.1, 48.8, 49.3, 59.2, 115.4, 137.4, 217.0. IR (neat) 3295, 2959, 1742, 1329, 1146, 1069 cm⁻¹. MS (ESI) calcd for C₁₅H₂₆NO₂S [M + H]⁺ 300.1628, found 300.1624.

Table 2. Intramolecular Aminohydroxylation of *N*-Alkenylsulfonamides

entry	substrate	product	time (h)	yield (%)
1			13	90
2			10	78
3 ^a			72	97
4			24	91 (dr = 55:45)
5			22	94 (dr = 50:50)
6 ^b			78	91 (dr = 52:48)
7			72	93 (dr = 54:46)
8 ^b			74	96
9 ^b			72	98
10 ^c			75	90 (dr = 54:46)
11 ^c			58	78 (dr = 66:34)
12 ^c			74	88
13 ^d			56	91 (dr = >99:<1)
14 ^d			72	82 (dr = 77:23)
15 ^d			71	78
16 ^a			99	91 (dr = 51:49)

^aReaction was carried out at room temperature. ^bOxone (2.0 equiv) was used. ^cOxone (2.0 equiv) was used in a 2:1 mixture of MeCN and H₂O. ^dReaction was carried out without TsOH·H₂O at 0 °C.


Scheme 2. Plausible Reaction Mechanism for Intramolecular Aminohydroxylation of *N*-Alkenylsulfonamides




General Procedure for the Intramolecular Aminohydroxylation of *N*-Alkenyl Sulfonamides (1) (Table 1, entry 10 and Table 2). To a solution of **1a** (59.8 mg, 0.25 mmol) and Oxone (230.5 mg,

0.375 mmol) in a 1:1 mixture (1.5 mL) of MeCN and H₂O was added TsOH·H₂O (4.8 mg, 0.025 mmol). The solution was stirred at 50 °C for 10 h. Saturated NaHCO₃ aqueous solution (10 mL) was added to the reaction mixture, and the product was extracted with AcOEt (15 mL × 3). The combined extracts were washed with brine (10 mL) and dried over Na₂SO₄. The organic phase was concentrated under reduced pressure and the crude product was purified by silicagel column chromatography (eluent: hexane/AcOEt = 2/1) to give desired product **2a** (63.8 mg, >99% yield) as a colorless oil.

(±)-1-(1-(4-Fluorophenyl)sulfonyl)pyrrolidin-2-yl)methanol (**2b**). White solid (58.3 mg, 90% yield) mp 69–70 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.45–1.54 (m, 1H), 1.65–1.77 (m, 2H), 1.77–1.89 (m, 1H), 2.68 (brs, 1H), 3.24 (dt, J = 10.4, 7.1 Hz, 1H), 3.48 (dt, J = 10.4, 6.2 Hz, 1H), 3.59–3.66 (m, 1H), 3.66–3.76 (m, 2H), 7.19–7.28 (m, 2H), 7.85–7.92 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 24.2, 28.9, 50.0, 61.9, 65.7, 116.5 (d, J_{C-F} = 23.0 Hz) (2C), 130.2 (d, J_{C-F} = 9.6 Hz) (2C), 133.0 (d, J_{C-F} = 3.8 Hz), 165.3 (d, J_{C-F} = 256.8 Hz). IR (KBr) 3534, 1493, 1332, 1237, 1155, 1093, 1042 cm⁻¹. MS (ESI) calcd for C₁₁H₁₄FNNaO₃S [M + Na]⁺ 282.0571, found 282.0567.

Scheme 3. Oxidative Transformation of **2** into **3**

^a**2g** (dr = 52:48) was used. ^b**2k** (dr = 54:46) was used.

Scheme 4. Synthesis of Proline Ethyl Ester **5a** by Desulfonation of *N*-Sulfonamide **4a**

(±)-(1-(4-Nitrophenyl)sulfonyl)pyrrolidin-2-yl)methanol (**2c**). Yellow solid (55.8 mg, 78% yield) mp 93–94 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.50–1.60 (m, 1H), 1.67–1.77 (m, 1H), 1.77–1.96 (m, 2H), 2.51 (brs, 1H), 3.27 (dt, *J* = 10.6, 7.1 Hz, 1H), 3.53 (dt, *J* = 10.6, 6.3 Hz, 1H), 3.64–3.78 (m, 3H), 8.06 (d, *J* = 8.9 Hz, 2H), 8.40 (d, *J* = 8.9 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 24.2, 28.8, 50.0, 62.1, 65.5, 124.4 (2C), 128.7 (2C), 142.9, 150.2. IR (neat) 3567, 1532, 1349, 1163, 1095 cm⁻¹. MS (ESI) calcd for C₁₁H₁₃N₂O₅S [M + H]⁺ 287.0696, found 287.0694.

(±)-(1-(4-Butylsulfonyl)pyrrolidin-2-yl)methanol (**2d**). Colorless oil (53.7 mg, 97% yield). ¹H NMR (400 MHz, CDCl₃) δ 0.96 (t, *J* = 7.6 Hz, 3H), 1.47 (sext, *J* = 7.6 Hz, 2H), 1.78–1.92 (m, 4H), 1.92–2.00 (m, 1H), 2.01–2.12 (m, 1H), 2.67 (brs, 1H), 2.99 (dd, *J* = 9.0, 7.1 Hz, 2H), 3.35–3.49 (m, 2H), 3.55–3.69 (m, 2H), 3.82–3.90 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 13.6, 21.7, 24.8, 25.1, 29.1, 48.9, 49.5, 61.5, 65.8. IR (neat) 3504, 1327, 1144, 1050 cm⁻¹. MS (ESI) calcd for C₉H₂₀NO₃S [M + H]⁺ 222.1158, found 222.1161.

(1-(1*S*)-10-Camphorsulfonyl)pyrrolidin-2-yl)methanol (**2e**, Diastereomer Mixtures). Colorless oil (71.7 mg, 91% yield, dr = 55:45). Major-diastereomer: ¹H NMR (400 MHz, CDCl₃) δ 0.90 (s, 3H), 1.14 (s, 3H), 1.38–1.49 (m, 1H), 1.61–1.72 (m, 1H), 1.81–2.16 (m, 7H), 2.34–2.44 (m, 1H), 2.47–2.59 (m, 1H), 2.81 (brs, 1H), 2.83 (d, *J* = 14.6 Hz, 1H), 3.42 (d, *J* = 14.6 Hz, 1H), 3.45–3.56 (m, 2H), 3.57–3.76 (m, 2H), 3.82–3.90 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 19.9, 20.1, 24.8, 25.4, 27.0, 29.3, 42.7, 42.9, 44.6, 48.2, 49.9, 58.5, 61.9, 65.8, 215.7. Minor-diastereomer: ¹H NMR (400 MHz, CDCl₃) δ 0.90 (s, 3H), 1.13 (s, 3H), 1.38–1.49 (m, 1H), 1.61–1.72 (m, 1H), 1.81–2.16 (m, 7H), 2.34–2.44 (m, 1H), 2.47–2.59 (m, 1H), 2.91 (d, *J* = 14.6 Hz, 1H), 2.92

(brs, 1H), 3.36 (d, *J* = 14.6 Hz, 1H), 3.39–3.45 (m, 1H), 3.45–3.56 (m, 1H), 3.57–3.76 (m, 2H), 3.90–3.98 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 19.9, 20.1, 25.0, 25.4, 27.0, 29.0, 42.7, 42.9, 45.8, 48.0, 49.6, 58.4, 62.1, 65.6, 216.0. IR (neat) 3502, 1743, 1146, 1050 cm⁻¹. MS (ESI) calcd for C₁₅H₂₆NO₄S [M + H]⁺ 316.1577, found 316.1572.

((5*S*)-5-Methyl-1-tosylpyrrolidin-2-yl)methanol (**2f**, Diastereomer Mixtures). Colorless oil (63.2 mg, 94% yield, dr = 50:50). Major-diastereomer: ¹H NMR (400 MHz, CDCl₃) δ 1.17 (d, *J* = 6.6 Hz, 3H), 1.56–1.66 (m, 1H), 1.79–1.89 (m, 1H), 2.02–2.19 (m, 2H), 2.43 (s, 3H), 2.60 (brs, 1H), 3.58–3.78 (m, 3H), 4.16–4.25 (m, 1H), 7.30 (d, *J* = 8.4 Hz, 2H), 7.76 (d, *J* = 8.4 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 20.2, 21.5, 27.9, 31.8, 57.8, 61.3, 65.5, 127.1 (2C), 129.6 (2C), 138.4, 143.2. Minor-diastereomer: ¹H NMR (400 MHz, CDCl₃) δ 1.34 (d, *J* = 6.4 Hz, 3H), 1.43–1.54 (m, 2H), 1.55–1.78 (m, 2H), 2.44 (s, 3H), 2.87 (brs, 1H), 3.58–3.67 (m, 2H), 3.67–3.85 (m, 2H), 7.33 (d, *J* = 8.1 Hz, 2H), 7.74 (d, *J* = 8.1 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 21.5, 23.2, 27.2, 31.7, 58.3, 63.3, 66.1, 127.6 (2C), 129.8 (2C), 134.3, 143.7. IR (neat) 3512, 1332, 1156, 1095, 1049 cm⁻¹. MS (ESI) calcd for C₁₃H₂₀NO₃S [M + Na]⁺ 270.1158, found 270.1155.

((5*R*)-5-Isopropyl-1-tosylpyrrolidin-2-yl)methanol (**2g**). The diastereomers were separated by column chromatography. White solid (67.6 mg, 91% yield, dr = 52:48). Major-diastereomer: ¹H NMR (400 MHz, CDCl₃) δ 0.92 (d, *J* = 7.9 Hz, 3H), 1.02 (d, *J* = 7.9 Hz, 3H), 1.16–1.27 (m, 1H), 1.50–1.69 (m, 3H), 1.92–2.02 (m, 1H), 2.44 (s, 3H), 3.00 (brs, 1H), 3.49 (td, *J* = 7.6, 3.9 Hz, 1H), 3.58–3.68 (m, 3H), 7.33 (d, *J* = 8.5 Hz, 2H), 7.73 (d, *J* = 8.5 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 17.8, 20.1, 21.5, 25.7, 27.1, 31.4, 63.0, 66.0, 68.4, 127.7 (2C), 129.7 (2C), 134.3, 143.7. Minor-diastereomer: ¹H NMR (400 MHz, CDCl₃) δ 0.49 (d, *J* = 7.0 Hz, 3H), 0.83 (d, *J* = 7.0 Hz, 3H), 1.68–1.76 (m, 1H), 1.77–2.02 (m, 3H), 2.42 (s, 3H), 2.36–2.46 (m, 1H), 2.61–2.68 (m, 1H), 3.76–3.85 (m, 3H), 3.94–4.00 (m, 1H), 7.29 (d, *J* = 8.1 Hz, 2H), 7.76 (d, *J* = 8.1 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 15.6, 19.8, 21.5, 23.8, 29.6, 29.8, 63.0, 65.3, 66.5, 126.8 (2C), 129.5 (2C), 138.5, 143.0. IR (KBr) 3520, 1469, 1328, 1155, 1045 cm⁻¹. MS (ESI) calcd for C₁₅H₂₄NO₃S [M + H]⁺ 298.1471, found 298.1472.

(±)-(2-Tosyl-2-azaspiro[4.5]decan-3-yl)methanol (**2j**). Colorless oil (79.2 mg, 98% yield). ¹H NMR (400 MHz, CDCl₃) δ 0.51–0.59 (m, 1H), 0.66–0.76 (m, 1H), 1.05–1.47 (m, 8H), 1.51 (dd, *J* = 12.9, 9.7 Hz, 1H), 1.73 (dd, *J* = 12.9, 7.5 Hz, 1H), 2.44 (s, 3H), 3.16 (d, *J* = 11.2 Hz, 1H), 3.29 (dd, *J* = 8.3, 5.1 Hz, 1H), 3.33 (d, *J* = 11.2 Hz, 1H), 3.51–3.59 (m, 1H), 3.66–3.74 (m, 1H), 3.74–3.83 (m, 1H), 7.33 (d, *J* = 8.5 Hz, 2H), 7.74 (d, *J* = 8.5 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 21.5, 22.7, 23.7, 25.7, 33.8, 36.2, 40.7, 41.5, 59.6, 61.5, 66.0, 127.5 (2C), 129.7 (2C), 134.0, 143.8. IR (neat) 3500, 1450, 1336, 1157, 1092, 1036 cm⁻¹. MS (ESI) calcd for C₁₇H₂₆NO₃S [M + Na]⁺ 324.1628, found 324.1624.

(±)-(cis-1-Tosyloctahydro-1*H*-indol-2-yl)methanol (**2k**, Diastereomer Mixtures). Colorless oil (69.6 mg, 90% yield, dr = 54:46). Major-diastereomer: ¹H NMR (400 MHz, CDCl₃) δ 0.99–1.02 (m, 1H), 1.02–1.30 (m, 2H), 1.31–1.75 (m, 5H), 1.85–1.88 (m, 1H), 2.21–2.24 (m, 2H), 2.43 (s, 3H), 2.64 (t, *J* = 6.8 Hz, 1H), 3.62–3.73 (m, 1H), 3.73–3.86 (m, 2H), 3.96 (dt, *J* = 11.0, 5.8 Hz, 1H), 7.30 (d, *J* = 8.1 Hz, 2H), 7.76 (d, *J* = 8.1 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 19.8, 21.5, 23.6, 25.8, 27.5, 30.8, 35.6, 59.7, 62.1, 66.6, 127.3 (2C), 129.6 (2C), 137.9, 143.2. Minor-diastereomer: ¹H NMR (400 MHz, CDCl₃) δ 1.02–1.30 (m, 3H), 1.31–1.75 (m, 7H), 1.92–2.03 (m, 1H), 2.44 (s, 3H), 3.17 (dd, *J* = 8.2, 4.8 Hz, 1H), 3.52–3.61 (m, 1H), 3.62–3.73 (m, 2H), 3.73–3.86 (m, 1H), 7.33 (d, *J* = 8.1 Hz, 2H), 7.73 (d, *J* = 8.1 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 20.1, 21.5, 24.3, 25.6, 30.9, 31.8, 36.0, 61.7, 62.6, 66.3, 127.4 (2C), 129.8 (2C), 134.6, 143.6. IR (neat) 3502, 1335, 1157, 1095, 1049 cm⁻¹. MS (ESI) calcd for C₁₆H₂₄NO₃S [M + H]⁺ 310.1471, found 310.1465.

(±)-(trans-1-Tosyloctahydro-1*H*-indol-2-yl)methanol (**2l**, Diastereomer Mixtures). Colorless oil (60.3 mg, 78% yield, dr = 66:34). Major-diastereomer: ¹H NMR (400 MHz, CDCl₃) δ 0.84–1.47 (m, 6H), 1.57–1.74 (m, 3H), 1.75–1.88 (m, 2H), 2.35 (td, *J* = 10.5, 3.4 Hz, 1H), 2.45 (s, 3H), 2.49–2.59 (m, 1H), 3.61–3.77 (m, 3H), 7.35 (d, *J* = 8.3 Hz, 2H), 7.71 (d, *J* = 8.3 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 21.5, 24.6, 25.2, 29.8, 32.6, 33.1, 43.8, 62.1, 66.9, 67.4, 128.0 (2C), 129.7 (2C), 133.0, 143.7. Minor-diastereomer: ¹H NMR (400 MHz, CDCl₃) δ 0.84–1.47 (m, 6H), 1.57–1.74 (m, 3H), 1.75–1.88 (m, 2H), 2.05–2.15

(m, 1H), 2.43 (s, 3H), 2.84 (ddd, $J = 11.6, 10.5, 3.4$ Hz, 1H), 3.04 (brs, 1H), 3.77–3.85 (m, 1H), 4.00–4.08 (m, 1H), 7.29 (d, $J = 8.2$ Hz, 2H), 7.74 (d, $J = 8.2$ Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 21.5, 25.06, 25.07, 29.5, 29.8, 33.8, 44.7, 62.9, 66.0, 66.6, 127.0 (2C), 129.7 (2C), 139.1, 143.1. IR (neat) 3505, 1340, 1157, 1095, 1045 cm^{-1} . MS (ESI) calcd for $\text{C}_{16}\text{H}_{24}\text{NO}_3\text{S}$ $[\text{M} + \text{H}]^+$ 310.1471, found 310.1468.

(\pm)-*syn*-1-(1-Tosylpyrrolidin-2-yl)ethanol (**2n**). White solid (61.2 mg, 91% yield, dr = >99:<1) mp 73–74 °C. ^1H NMR (400 MHz, CDCl_3) δ 1.18 (d, $J = 6.2$ Hz, 3H), 1.28–1.39 (m, 1H), 1.51–1.63 (m, 2H), 1.66–1.77 (m, 1H), 2.44 (s, 3H), 3.32–3.45 (m, 3H), 3.45–3.53 (m, 1H), 3.67–3.76 (m, 1H), 7.34 (d, $J = 8.1$ Hz, 2H), 7.75 (d, $J = 8.1$ Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 19.4, 21.5, 24.5, 28.4, 49.8, 66.4, 69.7, 127.6 (2C), 129.8 (2C), 134.2, 143.9. IR (KBr) 3523, 1327, 1153, 1105, 1079 cm^{-1} . MS (ESI) calcd for $\text{C}_{13}\text{H}_{20}\text{NO}_3\text{S}$ $[\text{M} + \text{H}]^+$ 270.1158, found 270.1158.

(\pm)-*anti*-1-(1-Tosylpyrrolidin-2-yl)ethanol (**2o**). Colorless oil (55.2 mg, 82% yield, dr = 77:23). ^1H NMR (400 MHz, CDCl_3) δ 1.17 (d, $J = 6.4$ Hz, 3H), 1.24–1.32 (m, 1H), 1.59–1.69 (m, 1H), 1.69–1.89 (m, 2H), 2.44 (s, 3H), 2.62 (brs, 1H), 3.32–3.43 (m, 2H), 3.48–3.54 (m, 1H), 4.15–4.24 (m, 1H), 7.34 (d, $J = 8.5$ Hz, 2H), 7.73 (d, $J = 8.5$ Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 18.3, 21.5, 24.5, 26.0, 50.5, 65.7, 69.0, 127.6 (2C), 129.7 (2C), 133.9, 143.7. IR (KBr) 3506, 1337, 1158, 1092, 999 cm^{-1} . MS (ESI) calcd for $\text{C}_{13}\text{H}_{19}\text{NNaO}_3\text{S}$ $[\text{M} + \text{Na}]^+$ 292.0978, found 292.0973.

(\pm)-*(2-Methyl-1-tosylpyrrolidin-2-yl)methanol* (**2p**). White solid (52.5 mg, 78% yield) mp 64–65 °C. ^1H NMR (400 MHz, CDCl_3) δ 1.25 (s, 3H), 1.58–1.68 (m, 1H), 1.71–1.93 (m, 2H), 2.14 (dt, $J = 12.4, 7.9$ Hz, 1H), 2.43 (s, 3H), 2.66 (brs, 1H), 3.33–3.41 (m, 1H), 3.48 (dt, $J = 9.4, 7.2$ Hz, 1H), 3.59 (dd, $J = 11.7, 5.4$ Hz, 1H), 3.89 (dd, $J = 11.7, 3.8$ Hz, 1H), 7.30 (d, $J = 8.3$ Hz, 2H), 7.75 (d, $J = 8.3$ Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 21.5, 22.2, 22.4, 38.1, 50.3, 68.9, 69.1, 127.2 (2C), 129.6 (2C), 137.8, 143.2. IR (KBr) 3527, 1325, 1152, 1094, 1052 cm^{-1} . MS (ESI) calcd for $\text{C}_{13}\text{H}_{19}\text{NNaO}_3\text{S}$ $[\text{M} + \text{Na}]^+$ 292.0978, found 292.0970.

General Procedure for the Transformation of *N*-Sulfonyl Prolinol Derivatives (2**) into *N*-Sulfonyl Proline Derivatives (**3**) by Oxidation with DIB/TEMPO System (Scheme 3).** To a solution of **2a** (63.8 mg, 0.25 mmol) and DIB (177.1 mg, 0.55 mmol) in a 1:1 mixture (1.5 mL) of MeCN and H_2O was added TEMPO (3.9 mg, 0.025 mmol), and the solution was stirred at room temperature for 12 h. Saturated NaHCO_3 aqueous solution (10 mL) was added to the reaction mixture. The product was basified to pH 10 with 1N NaOH aq., and washed with AcOEt (15 mL \times 3). The aqueous layer was acidified to pH 3 with 1N HCl aq., extracted with CHCl_3 (15 mL \times 3), and dried over Na_2SO_4 . The organic phase was concentrated under reduced pressure to give the desired product **3a** (59.2 mg, 88% yield) as a white solid without further purification.

(*5R*)-5-Isopropyl-1-tosylpyrrolidine-2-carboxylic acid (**3g**, Diastereomer Mixtures). White solid (72.3 mg, 93% yield, dr = 55:45). Major-diastereomer: ^1H NMR (400 MHz, CDCl_3) δ 0.93 (d, $J = 6.9$ Hz, 3H), 1.00 (d, $J = 6.9$ Hz, 3H), 1.34–1.45 (m, 1H), 1.71–1.87 (m, 2H), 2.02–2.17 (m, 2H), 2.45 (s, 3H), 3.53 (dd, $J = 11.9, 7.1$ Hz, 1H), 4.17 (dd, $J = 8.3, 6.2$ Hz, 1H), 7.35 (d, $J = 8.3$ Hz, 2H), 7.75 (d, $J = 8.3$ Hz, 2H), 9.25 (brs, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 17.2, 20.1, 21.6, 26.0, 28.3, 31.1, 62.0, 68.1, 127.7 (2C), 129.9 (2C), 133.8, 144.3, 175.2. Minor-diastereomer: ^1H NMR (400 MHz, CDCl_3) δ 0.51 (d, $J = 6.9$ Hz, 3H), 0.83 (d, $J = 6.9$ Hz, 3H), 1.70–1.84 (m, 1H), 1.96–2.19 (m, 3H), 2.24–2.37 (m, 1H), 2.43 (s, 3H), 3.98–4.04 (m, 1H), 4.51 (d, $J = 7.3$ Hz, 1H), 7.29 (d, $J = 8.2$ Hz, 2H), 7.74 (d, $J = 8.2$ Hz, 2H), 9.25 (brs, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 14.8, 19.7, 21.5, 23.7, 29.5, 29.8, 62.3, 64.9, 127.0 (2C), 129.4 (2C), 138.1, 143.2, 178.5. IR (KBr) 2965, 1728, 1344, 1159, 1090, 1019 cm^{-1} . MS (ESI) calcd for $\text{C}_{15}\text{H}_{22}\text{NO}_4\text{S}$ $[\text{M} + \text{H}]^+$ 312.1264, found 312.1258.

(\pm)-4,4-Dimethyl-1-tosylpyrrolidine-2-carboxylic acid (**3i**). White solid (70.6 mg, 95% yield). ^1H NMR (400 MHz, CDCl_3) δ 0.74 (s, 3H), 1.09 (s, 3H), 1.91–2.02 (m, 2H), 2.44 (s, 3H), 3.10 (d, $J = 10.0$ Hz, 1H), 3.21 (t, $J = 10.0$ Hz, 1H), 4.29 (t, $J = 8.0$ Hz, 1H), 7.34 (d, $J = 8.3$ Hz, 2H), 7.79 (d, $J = 8.3$ Hz, 2H), 10.43 (brs, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 21.6, 25.5, 25.7, 38.8, 44.2, 60.4, 60.7, 127.7 (2C), 129.7 (2C),

134.4, 144.0, 177.2. IR (KBr) 2963, 1729, 1345, 1159, 1093 cm^{-1} . MS (ESI) calcd for $\text{C}_{14}\text{H}_{20}\text{NO}_4\text{S}$ $[\text{M} + \text{H}]^+$ 298.1108, found 298.1104.

(\pm)-2-Tosyl-2-azaspiro[4.5]decane-3-carboxylic acid (**3j**). Colorless oil (75.9 mg, 80% yield). ^1H NMR (400 MHz, CDCl_3) δ 0.86–0.95 (m, 1H), 0.95–1.05 (m, 1H), 1.14–1.51 (m, 9H), 1.88–1.97 (m, 1H), 1.97–2.06 (m, 1H), 2.44 (s, 3H), 3.22 (d, $J = 10.6$ Hz, 1H), 3.25 (d, $J = 10.6$ Hz, 1H), 4.22 (t, $J = 8.2$ Hz, 1H), 7.34 (d, $J = 8.3$ Hz, 2H), 7.79 (d, $J = 8.3$ Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 21.5, 22.9, 23.5, 25.6, 34.1, 35.3, 42.2, 42.7, 58.1, 59.8, 127.7 (2C), 129.7 (2C), 134.2, 144.0, 176.8. IR (neat) 3545, 1729, 1346, 1156, 1093, 1056 cm^{-1} . MS (ESI) calcd for $\text{C}_{17}\text{H}_{24}\text{NO}_4\text{S}$ $[\text{M} + \text{H}]^+$ 338.1421, found 338.1411.

(\pm)-*cis*-1-Tosyl-2-azaspiro[4.5]decane-3-carboxylic acid (**3k**, diastereomer mixtures). White solid (80.8 mg, >99% yield, dr = 51:49). Major-diastereomer: ^1H NMR (400 MHz, CDCl_3) δ 1.01–1.35 (m, 3H), 1.36–1.72 (m, 4H), 1.72–1.82 (m, 1H), 2.03–2.13 (m, 2H), 2.19 (td, $J = 12.6, 8.9$ Hz, 1H), 2.45 (s, 3H), 2.54–2.65 (m, 1H), 3.66 (dt, $J = 11.0, 6.3$ Hz, 1H), 4.20 (t, $J = 8.9$ Hz, 1H), 7.34 (d, $J = 8.3$ Hz, 2H), 7.78 (d, $J = 8.3$ Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 20.3, 21.5, 23.4, 25.6, 29.5, 32.4, 37.3, 59.1, 60.5, 127.6 (2C), 129.5 (2C), 137.7, 143.4, 178.3. Minor-diastereomer: ^1H NMR (400 MHz, CDCl_3) δ 1.01–1.35 (m, 3H), 1.36–1.72 (m, 6H), 1.82–1.92 (m, 1H), 1.94 (dd, $J = 13.1, 6.3$ Hz, 1H), 2.33 (td, $J = 13.1, 9.6$ Hz, 1H), 2.43 (s, 3H), 3.75–3.86 (m, 1H), 4.40 (d, $J = 9.6$ Hz, 1H), 7.30 (d, $J = 8.3$ Hz, 2H), 7.79 (d, $J = 8.3$ Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 20.1, 21.5, 23.7, 25.6, 28.5, 32.6, 35.8, 59.7, 60.7, 127.6 (2C), 129.8 (2C), 135.0, 143.9, 177.6. IR (KBr) 2932, 1725, 1340, 1157, 1096 cm^{-1} . MS (ESI) calcd for $\text{C}_{16}\text{H}_{22}\text{NO}_4\text{S}$ $[\text{M} + \text{H}]^+$ 324.1264, found 324.1256.

Transformation of *N*-Tosyl Proline (3a**) into Proline Ethyl Ester (**5a**) by Detosylation under Mild Conditions (Scheme 4).** The solution of *N*-tosyl proline (**3a**) (53.8 mg, 0.20 mmol) and K_2CO_3 (55.2 mg, 0.40 mmol) in DMF (1.0 mL) was added EtI (24.1 μL , 0.30 mmol). The solution was stirred at room temperature for 14 h under argon atmosphere. 1N HCl solution (3 mL) was added to the reaction mixture, and the product was extracted with AcOEt (10 mL \times 3). The combined extracts were washed with brine (10 mL) and dried over Na_2SO_4 . The organic phase was concentrated under reduced pressure and the crude product was purified by silicagel column chromatography (eluent: hexane/AcOEt = 4/1) to give *N*-tosyl proline ethyl ester (**4a**) (59.4 mg, >99% yield) as a white solid.

The solution of *N*-tosyl proline ethyl ester (**4a**) (74.3 mg, 0.25 mmol) and phenol (47.0 mg, 0.50 mmol) and 25% HBr in acetic acid (1 mL) was stirred at room temperature for 24 h under argon atmosphere. This reaction mixture was concentrated under reduced pressure to give proline ethyl ester (**5a**) (52.6 mg, 94%) as a brown oil.

(\pm)-Ethyl pyrrolidine-2-carboxylate hydrobromide (**5a**). ^1H NMR (400 MHz, CDCl_3) δ 1.34 (t, $J = 7.3$ Hz, 3H), 2.02–2.27 (m, 3H), 2.41–2.53 (m, 1H), 3.53–3.69 (m, 2H), 4.32 (q, $J = 7.3$ Hz, 2H), 4.49–4.60 (m, 1H), 8.52 (brs, 1H), 10.3 (brs, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 14.1, 23.7, 28.8, 46.2, 59.3, 63.3, 168.7. IR (neat) 3227, 1739, 1630, 1241, 1043 cm^{-1} . MS (ESI) calcd for $\text{C}_7\text{H}_{14}\text{NO}_2$ $[\text{M}]^+$ 144.1019, found 144.1015.

■ ASSOCIATED CONTENT

☉ Supporting Information

^1H and ^{13}C NMR spectra of compounds in the intramolecular aminohydroxylation, in the oxidation using a DIB/TEMPO system, and in the derivatization in Scheme 4. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*moriyama@faculty.chiba-u.jp; togo@faculty.chiba-u.jp

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

Financial support in the form of a Grant-in-Aid for Scientific Research (No. 24750033) from the Ministry of Education,

Culture, Sports, Science and Technology in Japan (K.M.) and the Iodine Research Project in Chiba University is gratefully acknowledged.

REFERENCES

(1) For a review of methods for the construction of 1,2-aminoalcohols, see: Bergmeier, S. C. *Tetrahedron* **2000**, *56*, 2561–2576.

(2) For a review of aminohydroxylation, see: (a) Cardona, F.; Goti, A. *Nat. Chem.* **2009**, *1*, 269–275. (b) Donohoe, T. J.; Callens, C. K. A.; Flores, A.; Lacy, A. R.; Rathi, A. H. *Chem.—Eur. J.* **2011**, *17*, 58–76.

(3) (a) O'Hagan, D. *Nat. Prod. Rep.* **2000**, *17*, 435. (b) Lewis, J. R. *Nat. Prod. Rep.* **2001**, *18*, 95–128.

(4) (a) Sharpless, K. B.; Chong, A. O.; Oshima, J. *J. Org. Chem.* **1976**, *41*, 177–179. (b) Li, G.; Chang, H.-T.; Sharpless, K. B. *Angew. Chem., Int. Ed.* **1996**, *35*, 451–454. (c) Donohoe, T. J.; Churchill, G. H.; Wheelhouse, K. M. P.; Glossop, P. A. *Angew. Chem., Int. Ed.* **2006**, *45*, 8025–8028. (d) Kenworthy, M. N.; Taylor, R. J. K. *Org. Biomol. Chem.* **2005**, *3*, 603–611. (e) Donohoe, T. J.; Wheelhouse, K. M. P.; Lindsay-Scott, P. J.; Glossop, P. A.; Nash, I. A.; Parker, J. S. *Angew. Chem., Int. Ed.* **2008**, *47*, 2872–2875. (f) Donohoe, T. J.; Wheelhouse, K. M. P.; Lindsay-Scott, P. J.; Churchill, G. H.; Connolly, M. J.; Butterworth, S.; Glossop, P. A. *Chem. Asian J.* **2009**, *4*, 1237–1247. (g) Donohoe, T. J.; Lindsay-Scott, P. J.; Parker, J. S.; Callens, C. K. A. *Org. Lett.* **2010**, *12*, 1060–1063. (h) Donohoe, T. J.; Callens, C. K. A.; Lacy, A. R.; Winter, C. *Eur. J. Org. Chem.* **2012**, 655–663.

(5) (a) Alexanian, E. J.; Lee, C.; Sorensen, E. J. *J. Am. Chem. Soc.* **2005**, *127*, 7690–7691. (b) Szolcsányi, P.; Gracza, T. *Chem. Commun.* **2005**, 3948–3950.

(6) (a) Noack, M.; Göttlich, R. *Chem. Commun.* **2002**, 536–537. (b) Fuller, P. H.; Kim, J.-W.; Chemler, S. R. *J. Am. Chem. Soc.* **2008**, *130*, 17638–17639. (c) Paderes, M. C.; Chemler, S. R. *Org. Lett.* **2009**, *11*, 1915–1918. (d) Mancheno, D. E.; Thornton, A. R.; Stoll, A. H.; Kong, A.; Blakey, S. B. *Org. Lett.* **2010**, *12*, 4110–4113.

(7) de Haro, T.; Nevado, C. *Angew. Chem., Int. Ed.* **2011**, *50*, 906–910.

(8) (a) Serna, S.; Tellitu, I.; Domínguez, E.; Moreno, I.; SanMartin, R. *Tetrahedron* **2004**, *60*, 6533–6539. (b) Correa, A.; Tellitu, I.; Domínguez, E.; SanMartin, R. *J. Org. Chem.* **2006**, *71*, 8316–8319. (c) Tellitu, I.; Urrejola, A.; Serna, S.; Moreno, I.; Herrero, M. T.; Domínguez, E.; SanMartin, R.; Correa, A. *Eur. J. Org. Chem.* **2007**, 437–444. (d) Waedrop, D. J.; Bowen, E. G.; Forslund, R. E.; Sussman, A. D.; Weerasekera, S. L. *J. Am. Chem. Soc.* **2010**, *132*, 1188–1189. (e) Lovick, H. M.; Michael, F. E. *J. Am. Chem. Soc.* **2010**, *132*, 1249–1251.


(9) Li, H.; Widenhoefer, R. A. *Tetrahedron* **2010**, *66*, 4827–4831.

(10) Cochran, B. M.; Michael, F. E. *Org. Lett.* **2008**, *10*, 5039–5042.

(11) (a) Röben, C.; Souto, J. A.; González, Y.; Lishchynskyi, A.; Muñiz, K. *Angew. Chem., Int. Ed.* **2011**, *50*, 9478–9482. (b) K. Farid, U.; Wirth, T. *Angew. Chem., Int. Ed.* **2012**, *51*, 3462–3465.

(12) (a) Aggarwal, V. K.; Lopin, C.; Sandrinelli, F. *J. Am. Chem. Soc.* **2003**, *125*, 7596–7601. (b) Armstrong, A. *Angew. Chem., Int. Ed.* **2004**, *43*, 1460–1462. (c) Aggarwal, V. K.; Fang, G. Y. *Chem. Commun.* **2005**, 3448–3450.

(13) Treatment of *N*-(3-(oxiran-2-yl)propyl)tosylamide with TsOH-H₂O (10 mol%) in a mixture of MeCN and H₂O (1:1) at room temperature for 24 h gave **2a** in >99% yield.



(14) De Mico, A.; Margarita, R.; Parlanti, L.; Vescovi, A.; Piancatelli, G. *J. Org. Chem.* **1997**, *62*, 6974–6977.

(15) Lee, S.; Noda, K.; Aoyagi, H.; Kato, T.; Izumiya, N. *Int. J. Pept. Protein Res.* **1986**, *27*, 44–50.

(16) (a) Bender, C. F.; Widenhoefer, R. A. *J. Am. Chem. Soc.* **2005**, *127*, 1070–1071. (b) Sherman, E. S.; Fuller, P. H.; Kasi, D.; Chemler, S. R. *J. Org. Chem.* **2007**, *72*, 3896–3905. (c) DeNinno, M. P.; Andrews, M.; Bell, A. S.; Chen, Y.; Eller-Zarbo, C.; Eshelby, N.; Etienne, J. B.; Moore, D. E.; Palmer, M. J.; Visser, M. S.; Yu, L. J.; Zavadski, W. J.; Gibbs, E. M. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 2537–2541. (d) Narisada, M.;

Ohtani, M.; Watanabe, F.; Uchida, K.; Arita, H.; Doteuchi, M.; Hanasaki, K.; Kakushi, H.; Otani, K.; Hara, S. *J. Med. Chem.* **1988**, *31*, 1847–1854. (e) Liwosz, T. W.; Chemler, S. R. *J. Am. Chem. Soc.* **2012**, *134*, 2020–2023. (f) Donohoe, T. J.; Lindsay-Scott, P. J.; Parker, J. S.; Callens, C. K. A. *Org. Lett.* **2010**, *12*, 1060–1063.

(17) (a) Thai, K.; Wang, L.; Dudding, T.; Bilodeau, F.; Gravel, M. *Org. Lett.* **2010**, *12*, 5708–5711. (b) Li, G.-I.; Zhao, G. *Org. Lett.* **2006**, *8*, 633–636. (c) Nikolín, A. A.; Arkhipov, D. E.; Shipov, A. G.; Kramarova, E. P.; Koval'chuk, N. A.; Korlyukov, A. A.; Negrebetsky, V. V.; Baukov, Y. I.; Bassindale, A. R.; Taylor, P. G.; Bowden, A.; Bylikin, S. Y. *Chem. Heterocycl. Compd.* **2012**, *47*, 1565–1583.